BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 11, 2026
Home » Topics » Science

Science
Science RSS Feed RSS

Neurons

Study finds potential entry points to Huntington's therapy

March 1, 2022
By John Fox
A Chinese study led by researchers at Fudan University in Shanghai has described a novel strategy to target the "undruggable" mutant Huntingtin protein by screening for compounds that directly bind to the 'undruggable' target and rescue disease-relevant phenotypes.
Read More
Skeletal system

Study identifies potential new bone disease target

Feb. 28, 2022
By John Fox
Scientists at Osaka University have discovered that intercellular communication via extracellular vesicles from osteoblasts, cells that are specialized for laying down new bone, is a key factor for the transition from bone formation to resorption via a microRNA (miRNA)-mediated mechanism.
Read More
Coronavirus and DNA

Risk SNP for COVID-19 signals protection against HIV

Feb. 25, 2022
By Anette Breindl
A study from the Max Planck Institute for Evolutionary Anthropology and the Karolinska Institute has shown that individuals who carry the major genetic risk variant for severe COVID-19 infection are less likely to contract HIV.
Read More
Lung illustration

Lung microbiome affects brain immune cells

Feb. 25, 2022
By Anette Breindl
Antibiotic treatment that changed the lung microbiome affected the activity of microglia, the brain-specific version of macrophages, and could prevent the development of the multiple sclerosis model experimental autoimmune encephalitis in mice.
Read More
Cardiovascular illustration

Novel target identified for long QT

Feb. 23, 2022
By Subhasree Nag
Timothy syndrome, a rare autosomal-dominant disorder, is characterized by presence of a heart arrhythmia (long QT syndrome), which causes the cardiac muscle to take longer than usual to recharge between beats and can result in sudden death. Now scientists at Columbia University have discovered that a common FDA-approved over-the counter cough suppressant, dextromethorphan, can shorten the prolonged QT intervals in both cellular and mouse models of TS.
Read More
Microscopic visualization of a cancerous cell

EBV antibodies put to good use through retargeting

Feb. 22, 2022
By Anette Breindl
Researchers at Inserm have developed a method to direct pre-existing antibodies toward new targets. Their bimodular fusion proteins could be a broadly useful method for expanding access to antibody therapy. In a study that appeared in the Feb. 11, 2022, issue of Science Advances, the teams showed that antibodies to Epstein-Barr virus (EBV), which are present in 95% of the global population, could be redirected to a target cell of their choosing by fusing an EBV antigen to a cellular targeting ligand.
Read More
Neurology illustration

Engineered Wnt ligands repair BBB in neuro disorders

Feb. 22, 2022
By John Fox
An international study led by scientists at the Free University of Brussels in Belgium has shown that Wnt ligand signaling specificity is adjustable and may represent a means of treating CNS disorders by normalizing blood-brain barrier (BBB) function.
Read More
Rendering of splint on trachea

Georgia Tech 3D-printed splint to sub for missing windpipe in newborns

Feb. 18, 2022
By David Godkin
Engineers at Atlanta-based Georgia Tech’s Center for 3D Medical Fabrication have developed a 3D-printed tracheal splint as an airway for children born with a rare condition known as tracheal agenesis or the absence of a trachea or windpipe.
Read More
Microscopic visualization of a cancerous cell

EBV antibodies put to good use through retargeting

Feb. 18, 2022
By Anette Breindl
Researchers at Inserm have developed a method to direct pre-existing antibodies toward new targets. Their bimodular fusion proteins could be a broadly useful method for expanding access to antibody therapy. In a study that appeared in the Feb. 11, 2022, issue of Science Advances, the teams showed that antibodies to Epstein-Barr virus (EBV), which are present in 95% of the global population, could be redirected to a target cell of their choosing by fusing an EBV antigen to a cellular targeting ligand.
Read More
HIV-infected T cells

CROI 2022: Predicting the future to get ahead of viruses

Feb. 17, 2022
By Anette Breindl
Broadly neutralizing antibodies are one of the most powerful weapons against HIV. And like everything that is effective in the fight against HIV, they are hard to come by.
Read More
Previous 1 2 … 66 67 68 69 70 71 72 73 74 … 193 194 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 10, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld
    Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • Connecting puzzle pieces

    Korsana boosts Alzheimer’s work with reverse merger, $380M financing

    BioWorld Science
    Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing